2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-129811
    Bis-ANS dipotassium 65664-81-5 ≥99.0%
    Bis-ANS dipotassium is a fluorescent probe of hydrophobic protein. Bis-ANS binds to tubulin with a Kd of 2 μM. Bis-ANS dipotassium is a potent biphasic modulator of protein liquid-liquid phase separation (LLPS). Bis-ANS dipotassium promotes LLPS at low concentrations but suppresses LLPS at high concentrations.
    Bis-ANS dipotassium
  • HY-132814
    Fosgonimeton 2093305-05-4 98.24%
    Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models.
    Fosgonimeton
  • HY-136181
    YNT-185 dihydrochloride 1804978-82-2 ≥98.0%
    YNT-185 dihydrochloride is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 dihydrochloride ameliorates narcolepsy-cataplexy symptoms in mouse models.
    YNT-185 dihydrochloride
  • HY-14406A
    L-733060 hydrochloride 148687-76-7 ≥99.0%
    L-733060 hydrochloride is a potent tachykinin NK1 receptor antagonist. L-733060 hydrochloride inhibits neurogenic plasma extravasation at doses that do not cause adverse cardiovascular effects in rodents and also acts as an antitumoral agent.
    L-733060 hydrochloride
  • HY-145580
    Minzasolmin 1802518-92-8 98.60%
    Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models.
    Minzasolmin
  • HY-148948
    Nampt activator-3 2790481-63-7 99.71%
    NAMPT activator-3, a NAT derivative, is a NAMPT activator with an EC50 of 2.6 μM and a KD of 132 nM. NAMPT activator-3 effectively protects cultured cells from FK866 (HY-50876)-mediated toxicity. NAMPT activator-3 exhibits strong neuroprotective efficacy in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model without any overt toxicity.
    Nampt activator-3
  • HY-150793
    SY-LB-57 2253719-35-4 99.66%
    SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension.
    SY-LB-57
  • HY-155021
    PROTAC α-synuclein degrader 5 2781922-42-5 99.95%
    PROTAC α-synuclein degrader 5 is a highly selective small-molecule degrader (PROTAC) of α-synuclein aggregates, with a DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research.
    PROTAC α-synuclein degrader 5
  • HY-156586
    Egalognastat 1884154-02-2 99.63%
    Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease).
    Egalognastat
  • HY-158155
    CVN293 2815296-08-1 99.91%
    CVN293 is a selective and brain permeable potassium ion (K+) channel KCNK13 inhibtor with IC50s of 41 nM and 28 nM for hKCNK13 and mKCNK13, respectively. CVN293 potently inhibits the NLRP3-inflammasome mediated production of the proinflammatory cytokine IL-1β in microglia.
    CVN293
  • HY-158202
    ATF4-IN-2 2991057-60-2 99.24%
    ATF4-IN-2 (Compound 29) is a ATF4 inhibitor with a IC50 value of 47.71 nM. ATF4-IN-2 can be used in the study of neurodegenerative diseases.
    ATF4-IN-2
  • HY-18940A
    Cilobradine hydrochloride 186097-54-1 ≥99.0%
    Cilobradine hydrochloride is a HCN channel blocker. Cilobradine hydrochloride induces cardiac pacemaker currents and produces antidepressant effects.
    Cilobradine hydrochloride
  • HY-19627A
    Naldemedine tosylate 1345728-04-2
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
    Naldemedine tosylate
  • HY-B0075S
    Melatonin-d4 66521-38-8 ≥99.0%
    Melatonin-d4 is deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Antioxidative and anti-inflammatory properties. Melatonin is a selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation.
    Melatonin-d4
  • HY-B0549A
    Flavoxate hydrochloride 3717-88-2 99.70%
    Flavoxate hydrochloride is a potent and competitive phosphodiesterase (PDE) inhibitor. Flavoxate hydrochloride is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate hydrochloride shows moderate calcium antagonistic activity and local anesthetic effect. Flavoxate hydrochloride can be used for the research of overactive bladder (OAB) and lower urinary tract infections.
    Flavoxate hydrochloride
  • HY-B0653A
    Levobupivacaine hydrochloride 27262-48-2 99.86%
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine hydrochloride
  • HY-B0886A
    Iproniazid 54-92-2 ≥98.0%
    Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity.
    Iproniazid
  • HY-N0110B
    Palmatine hydroxide 131-04-4 99.64%
    Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine hydroxide
  • HY-N0420R
    Succinic acid (Standard) 110-15-6 99.97%
    Succinic acid (Standard) is the analytical standard of Succinic acid. This product is intended for research and analytical applications. Succinic acid is an anti-anxiety agent with oral activity. Disodium succinate is the salt form of Succinic acid. Succinic acid is an intermediate product of the tricarboxylic acid cycle. Succinic acid is an important platform chemical. Succinic acid can be used as surfactant, additive, ion chelating agent, flavoring agent and other applications in chemical, pharmaceutical and food fields.
    Succinic acid (Standard)
  • HY-N0473S
    L-Tyrosine-d4 62595-14-6 ≥98.0%
    L-Tyrosine-d4 is a deuterium labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
    L-Tyrosine-d4
Cat. No. Product Name / Synonyms Application Reactivity